CEO Sells Stock in Surge Biotech | Business and Finance News

CEO Jon Congleton executed a pre-arranged, rule 10b5-1 stock sale of 10,700 shares at $27.20 apiece, netting over $291K — while still holding a substantial 603K shares — as Mineralys Therapeutics, a biopharma firm targeting hypertension with its clinical-stage drug lorundrostat, continues to surge with a 90% year-over-year stock gain and a $2B market cap. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6d0b8cc30b5df677